tbuckley/cabot-search huggingface dataset:
Prognostic Significance of VLA4 and CD44 Expression by Flow Cytometry in Multiple Myeloma (MM)
Authors: Wasif Riaz, John Pham, Ling Zhang, Lynn Moscinski, Lori A Hazlehurst, Michael Emmons, Daniel M Sullivan, Kenneth H Shain, Conor Lynch, Yue Binglin, Hui-Yi Lin, Rachid Baz
Journal: Blood (2012)
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).
Authors: David F. McDermott, Charles G. Drake, Mario Sznol, Toni K. Choueiri, John Powderly, David C. Smith, Jon Wigginton, Dan McDonald, Georgia Kollia, Ashok Kumar Gupta, Michael B. Atkins
Journal: Journal of Clinical Oncology (2012)

4505 Background: BMS-936558 is a fully human monoclonal antibody that blocks the programmed death-1 co-inhibitory receptor (PD-1) expressed by activated T cells. In the initial portion of a phase I study, BMS-936558 showed promising activity in patients (pts) with various solid tumors, including mRCC. We expanded accrual in order to better characterize antitumor and dose effects. Methods: RCC pts were treated with BMS-936558 administered IV Q2WK at 10 mg/kg initially, followed by additional pts at 1 mg/kg. Pts received up to 12 cycles (4 doses/cycle) of treatment or until PD or CR. Clinical activity was assessed by RECIST 1.0. Results: Of 240 pts treated as of July 1 2011, 33 had mRCC and were treated at 1 (n=17) or 10 mg/kg (n=16). ECOG performance status was 0/1 in 13/19 pts. The number of prior therapies was 1 (n=10), 2 (n=9), or ≥3 (n=14), and included prior immunotherapy (n=20) or antiangiogenic therapy (n=24); 31 pts had prior nephrectomy. Sites of metastatic disease included lymph node (n=26), liver (n=7), lung (n=28), and bone (n=10). Median duration of therapy was 19 wk (max 96 wk). The incidence of grade 3-4 related AEs was 12% and included hypophosphatemia (6%), elevated ALT (3%), and cough (3%). Clinical activity was observed at both dose levels (Table). Some pts had a persistent reduction in overall tumor burden in the presence of new lesions and were not categorized as responders. Responses were noted in pts with visceral and bone metastases. Among the responders who were first treated ≥1 yr prior to data lock, 4 of 5 pts treated at 10 mg/kg had OR duration ≥1 yr, and 1 of 2 pts treated at 1 mg/kg was still on study with OR duration of 17.5 mo. Although the data for pts treated at 1mg/kg are not mature, the estimated progression-free survival (PFS) rate at 24 wk in pts receiving 10 mg/kg was 67% (Table). Conclusions: BMS-936558 is well tolerated and has durable clinical activity in pts with previously treated mRCC. Further development of BMS-936558 in pts with mRCC is ongoing. [Table: see text]
Novel Mouse Model for Testing NADPH Oxidase (Nox2) Role in Insulin Resistance Mediated Endothelial Dysfunction
Authors: P Sukumar, H Viswambharan, H Imrie, R M Cubbon, N Yuldasheva, M Gage, S Galloway, A Skromna, P Kandavelu, J Smith, V K Gatenby, D J Beech, S B Wheatcroft, K M Channon, A M Shah, Kearney
Journal: Circulation (2012)
Chimeric MEF2D and Dazap1 Fusion Proteins Are Created by a Variant t(1;19)(q23;p13.3) in Acute Lymphoblastic Leukemia (ALL).
Authors: Victor Prima, Lia Gore, Aimee Caires, Theresa Boomer, Miyako Yoshinari, Imaizume Masue, Varella-Garcia Marileila, Stephen P. Hunger
Journal: Blood (2004)
Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen
Authors: J.-P. Guastalla, A.-C. Hardy-Bessard, J.-F. Geay, H. Cure, I. Ray-Coquard, D. Paraiso, E. Pujade-Lauraine
Journal: Journal of Clinical Oncology (2004)

818 Background: The combination of doxorubicin (Dox) and docetaxel [Taxotere (T)] is one of the most active chemotherapeutic regimens in breast cancer. Pegylated liposomal doxorubicin [Caelyx (CA)] has a more favorable pharmacokinetic and toxicity (tox) profile, with comparable efficacy as monotherapy in MBC, compared with conventional Dox. We conducted a phase I study to determine the safety, feasibility, and dose limiting tox (DLT) of the CAT regimen, substituting CA for Dox in combination with T. Methods: Escalating doses of CA (30–35 mg/m2, day 1) were administered as a 30-min infusion every 4 weeks with bimonthly administration of T (40–50 mg/m2, day 1 & 15) in a 1H infusion, without initial growth factor support. DLT was defined as febrile neutropenia, prolonged neutropenia, or grade (gr.) 3 to 4 non-hematologic tox that occurred during the 1st cycle (Cy). The combination was considered acceptable if not interrupted for tox and if the received/planned dose-intensity (DI) was ≥90% during 6 scheduled Cy. Results: 13 patients (pts) with MBC and no prior chemotherapy (CT) for metastatic disease were enrolled. Dose level 1, with CA and T at doses of 30 and 50 mg/m2, respectively, induced DLT (prolonged gr. 4 neutropenia) at Cy 1 in 1/5 pts. Two pts had early progression, and CT was considered unacceptable in the 2 remaining pts (early termination - pulmonary embolism and DI <90% - repeated delays from prolonged neutropenia). Dose level 2, with CA and T at doses of 35 and 40 mg/m2, respectively, induced DLT (gr. 3 palmar-plantar erythrodysesthesia [PPE]) in 1/8 pts at Cy 1. Out of the 7 remaining pts at dose level 2, 6 completed 6 Cy with DI >90%. The most severe tox observed per pt were gr. 4 neutropenia (3 pts), gr. 2 PPE (3 pts), gr. 2 alopecia (2 pts), and gr. 2 mucositis (1 pt). Four pts experienced course delays and needed G-CSF support, and 1 additional pt had a dose reduction at Cy 6. No decrease of LVEF was observed. Conclusions: The administration of CA (35 mg/m2, d1) with T (40 mg/m2, d1 & 15) every 4 weeks is feasible. The CAT regimen is associated with acceptable and easily manageable tox. It merits further evaluation in MBC, a phase II study is planned. No significant financial relationships to disclose.
Removal of Donor CD4+ T Cells Markedly Promotes Graft-Versus-Tumor (GVT) Effects and Inhibits GVHD-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic BMT.
Authors: William J. Murphy, Lisbeth A. Welniak, Minghui Li, Thomas J. Sayers, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Kai Sun
Journal: Blood (2006)
Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
Authors: Stephan A. Grupp, Shannon L Maude, Pamela A Shaw, Richard Aplenc, David M. Barrett, Colleen Callahan, Simon F. Lacey, Bruce L. Levine, J Joseph Melenhorst, Laura Motley, Susan R. Rheingold, David T Teachey, Patricia A. Wood, David Porter, Carl H. June
Journal: Blood (2015)
Does pre-operative aspirin and statin prescription modulate the post-operative systemic inflammatory response following surgery for colorectal cancer?
Authors: David G. Watt, James Hugh Park, Shoukee K Ng, Paul G. Horgan, Donald C McMillan
Journal: Journal of Clinical Oncology (2016)

596 Background: Aspirin use has been reported to reduce the pre-op systemic inflammatory response (SIR) in patients with colorectal cancer (CRC). Moreover, an exaggerated post-op SIR, evidenced by C-reactive protein (CRP) concentrations, is associated with poorer short and long term outcomes, highlighting the importance of CRP as a potential therapeutic target for improving outcomes following surgery for CRC. Drugs such as corticosteroids, aspirin and statins may modulate the post-op SIR, but there is little current evidence supporting this hypothesis. Therefore, the aim of the present study was to determine whether pre-op prescription of aspirin or statins modulated the post-op SIR in patients undergoing surgery for CRC. Methods: Included patients were obtained from a prospectively maintained database of CRC resections from a single institution (2010-2014). The relationship between pre-op aspirin and statin prescription and post-op CRP concentrations was examined. Results: 446 patients were included. The majority of patients were &gt; 65 yrs (64%), male (57%) and underwent elective surgery (91%). 120 patients were prescribed aspirin and 187 prescribed statins with 100 patients prescribed both. Patients prescribed aspirin had a reduced post-op SIR particularly on day 3 (p = 0.009), 4 (p = 0.003) and 5 (p = 0.005). This effect was also observed following elective surgery (n = 402) on day 3 (p = 0.014), day 4 (p = 0.009) and day 5 (p = 0.019). Patients prescribed a statin also had a reduced post-op SIR, particularly on days 3 (p = 0.010), 4 (p = 0.006) and 5 (p = 0.017) and also following elective surgery on day 3 (p = 0.039) and day 4 (p = 0.039). The combination of aspirin and statin, compared with none or each on its own, resulted in the lowest post-op SIR, particularly on day 3 (p = 0.015), day 4 (p = 0.006) and day 5 (p = 0.023). Conclusions: Pre-op prescription of aspirin or statins resulted in a reduced post-op SIR following surgery for CRC. Therefore, pre-op use of these medications may be of benefit in improving outcomes, by reducing the post-op SIR – a reported predictor of both long and short term outcomes, following surgery for CRC.
TCT-2 Early or late intervention in patients with transient ST-segment elevation acute coronary syndromes: subgroup analysis of the ELISA-3 trial
Authors: Erik A. Badings, Wouter Remkes, Salem H. The, Jan-Henk E. Dambrink, Jan Van Wijngaarden, Geert Tjeerdsma, Saman Rasoul, Jorik Timmer, Marloes Van Der Wielen, Dirk J. Lok, Rik Hermanides, Arnoud van 't Hof
Journal: Journal of the American College of Cardiology (2015)
TCT-316 Characteristics Of Culprit Lesions Vs. Non-Culprit Lesions In Patients With ST-Elevation Myocardial Infarction – An Optical Coherence Tomography Study. On Behalf Of The TOTAL-OCT Investigators
Authors: Natalia Pinilla-Echeverri, Tej Sheth, Ravinay Bhindi, Sanjit Jolly, Olli A. Kajander
Journal: Journal of the American College of Cardiology (2015)
A forward-pulling technique for complicated Trapezoid basket impaction during retrieval of common bile duct stones
Authors: Tadahisa Inoue, Kiyoaki Ito, Norimitsu Ishii, Yuji Kobayashi, Masashi Yoneda
Journal: Endoscopy (2016)

Although basket impaction rarely occurs during retrieval of common bile duct stones, it is a potentially serious event [1]. The Trapezoid RX wire-guided retrieval basket (Boston Scientific Corp., Marlborough, Massachusetts, USA) has an emergency release feature, whereby the tip is designed to disengage, thereby facilitating basket removal and reducing the risk of impaction [2]. However, we encountered a rare case of trapezoid basket impaction that was complicated by difficulties in detaching the outer sheath from the basket wires.
SSRI exposure in pregnancy linked to speech disorders in offspring
Authors: Jacqui Wise
Journal: BMJ (2016)

A significant rise in the risk of speech and language disorders was found among children born to mothers prescribed selective serotonin reuptake inhibitors (SSRIs) during pregnancy, a study published in JAMA Psychiatry has found.

The prospective birth cohort study identified live births from 1996 to 2010 in a Finnish medical birth registry and found data on the mother’s prescription drug purchases in a drug reimbursement register.1 The final study cohort of 56 340 infants was divided into three groups. The medicated …
Ptprg and BCR/ABL1 Expression In CML Patients At Diagnosis and Upon TKI Treatment: Preliminary Results
Authors: Maria Monne, Giovanna Piras, Marzia Vezzalini, Antonella Uras, Marco Murineddu, Mohamed A. Yassin, Nader I Al-Dewik, Giancarlo Latte, Claudio Sorio
Journal: Blood (2013)
Multi-modality endoscopic management of a submucosal pancreas-perforating gastric foreign body
Authors: Christopher Lim, Peter Cosman, Milan Bassan
Journal: Endoscopy (2016)

A 60-year-old man presented to hospital with 3 days of epigastric pain after inadvertent ingestion of a fishbone. A computed tomography (CT) scan showed a hyperdense linear object measuring 5 cm that was embedded within the posterior wall of the stomach and extending towards the pancreas, in keeping with a perforating fishbone ([Fig. 1]). There was minimal free gas and no contrast leakage was noted on the scan. Given the location of the fishbone in the lesser sac, laparoscopic removal was thought to be technically challenging, so an attempt at endoscopic extraction was made to try to avoid him having to undergo a laparotomy.
Use of Internet among cancer patients and their relatives in Spain
Authors: M. López, J. Feliú, E. Espinosa, B. Castelo, J. de Castro, C. Belda-Iniesta, M. Sereno, R. Madero, F. Lobo, M. González Barón
Journal: Journal of Clinical Oncology (2008)

20704 Background: The use of Internet as a source of medical information by cancer patients has not been widely studied. Our purpose was to examine the kind of information collected from the web by cancer population as well as the barriers to its use, degree of satisfaction and its effects on the relationship between patient and clinician. Methods: Between June 2006 and September 2007, 109 patients (pts) and 67 relatives were approached in a tertiary hospital and two national health clinics. Ninety-nine patients and 66 relatives completed a structured interview. Information requested included social and demographic data, cancer specific questions and subjective perceptions after the searching the web. Results: 18.2% of pts and 66.7% of cancer relatives used Internet for searching medical information, being the more requested enquiries those concerning general information about the disease (88.2% and 52.9% among pts and relatives respectively) and treatment options (47% of pts and 41.2% of relatives). 77.8% estimated that the search had not helped them in making decisions, though 66.7% considered it had been useful in someway. The main reason for not using the web among pts was their preference to obtain it from physicians (44%) and, secondly, the lack of access to a computer (33.9%); among non users, 45.2% would have desired to have the chance. Regarding the degree of satisfaction, 33% of pts and 46% of relatives felt more confused. Only 11% of patients had discussed the findings with the physician, though from them the 85.7% considered the discussion had been of any help. Conclusions: The use of Internet to obtain cancer related information is not very extended in our country, though many patients and relatives would desire to do so. Besides, between users, the degree of satisfaction achieved is low, and only a reduced subgroup discusses the findings with the physician. Therefore, public health authorities should contemplate the elaboration of newer guidelines in the web aimed at cancer population in an effort to improve the information offered. No significant financial relationships to disclose.
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors
Authors: Jie Jiang, Fu Gui, Zhixiang He, Li Li, Yunzhan Li, Shunying Li, Xinrui Wu, Zhou Deng, Xihuan Sun, Xiaoxing Huang, Wei Huang, Shang Han, Ting Zhang, Zheng Wang, Bo Jiao, Siyang Song, Hongrui Wang, Lanfen Chen, Dawang Zhou, Qiang Liu, Ruibao Ren, Jianming Zhang, Xianming Deng
Journal: Cancer Research (2016)

Approximately 80% of breast cancers overexpress the kinase breast tumor kinase (BRK)/protein tyrosine kinase 6, which has various oncogenic roles in breast cancer cell proliferation, survival, and migration. However, BRK inhibitors have yet to be explored as possible therapeutic tools. In this study, we used a parallel compound-centric approach to discover a new class of pharmaceutical agents, exemplified by XMU-MP-2, as potent and selective BRK inhibitors. XMU-MP-2 exhibited target-specific inhibition of BRK kinase activity and disrupted signaling pathways mediated by this activity, thereby reducing proliferation in BRK-positive breast cancer cells. In mouse xenograft models, XMU-MP-2 repressed the growth of tumors driven by oncogenic BRK, including BRK-transformed Ba/F3 cells and BRK-positive breast cancer cells. Notably, XMU-MP-2 cooperated strongly with HER2 inhibitor or ER blockade to block breast cancer cell proliferation in vitro and in vivo Overall, our findings offer a preclinical proof of concept for therapeutic targeting of the BRK kinase in breast cancer. Cancer Res; 77(1); 175-86. ©2016 AACR.
TCT-199 A Comparative Analysis Of Use Of Extracorporeal Membrane Oxygenation And Peripheral Ventricular Assist Device TandemHeart In Acute Myocardial Infarction
Authors: Smita I. Negi, Maan Malahfji, Mladen Sokolovic, Rebecca Torguson, Romain Didier, Igor Gregoric, Pranav Loyalka, Augusto Pichard, Lowell F. Satler, Biswajit O. Kar, Ron Waksman
Journal: Journal of the American College of Cardiology (2015)
Metastatic carcinoid tumour (MCT): 20 years experience at the Queen Elizabeth Hospital. Does management by a medical oncology unit (MOU) improve outcome?
Authors: A. R. Townsend, S. Yeend, C. Luke, K. B. Pittman, K. Patterson, T. J. Price
Journal: Journal of Clinical Oncology (2008)

15581 Background: MCTs have unique treatment approaches and often have an indolent course. Until recently, data on survival and treatment outcome was limited by the infrequent nature of these tumors. We aim to retrospectively assess the impact of care by a MOU (as a measure of active multidisciplinary intervention) on patient outcome. Methods: Patients diagnosed with carcinoid tumors at the QEH/LMH after 1/1/1985 were identified from the SA cancer registry. For patients with MCT the following data was collected; histology, primary site, treatment and survival. Patients with MCT were classified into two groups; those managed by a MOU, and those managed by an alternative specialist (other). The characteristics and outcomes of these groups were compared. Results: 90 patients with carcinoid were identified; mean age = 63, M/F=50/40. The primary site of disease (MCT v local) was: small bowel 54% v 20%, lung 2% v 30%, large bowel 17% v 2%, appendix 0% v 18%. Of the patients with MCT (n=46), 25 were referred to a MOU. The median age for MOU v other was 62 v 75 yrs. Treatment received by the two groups (MOU v other) was; octreotide LAR (76% v 10%), resection of primary tumor (76% v 86%), liver resection (4% v 5%), chemotherapy (8% v 0%), and MIBG (12% v 5%). The median time from diagnosis to commencement of octreotide LAR was 19.6 mths for functional MCT, with >50% reduction in 5HIAA to initial treatment in 79% of patients and no deaths in responders. Median overall survival (MOU v other) was 112 mths v 32 mths (HR 3.07 (1.43 - 7.65), p=0.005), and 10yr survival was 40% v 17%. Survival increased with octreotide LAR use (112 mths v 53 mths, p=0.017) and resection of primary (93 mths v 21 mths, p=0.02). Using Cox proportional hazards regression analysis, age at diagnosis and site of primary disease did not significantly affect survival. The impact of year of diagnosis on outcome will be presented. Conclusions: This single centre experience suggests active multidisciplinary intervention improves survival. Patients not seen in a MOU received minimal observation and few received octreotide LAR. Outcome may reflect referral bias, as referral to a MOU increased in the past 10 years, when more interventions have become available. No significant financial relationships to disclose.
Correlation of <i>RASGRP1/APTX</i> ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination.
Authors: G. Martinelli, S. Paolini, C. Papayannidis, E. Ottaviani, S. Parisi, I. Iacobucci, A. Curti, D. Cilloni, G. Saglio, A. Candoni, M. Baccarani
Journal: Journal of Clinical Oncology (2010)

6550 Background: We conducted a phase I-II study aiming to assess efficacy and toxicity of tipifarnib-bortezomib treatment in elderly AML patients. RASGRP1/APTX genetic ratio, which is associated with treatment response in patients treated with tipifarnib alone, was tested. Methods: Eighty patients were enrolled with secondary-AML: 14 had high-risk cytogenetics; 42 were previously untreated. Seventy-five patients were treated. Results: Nine patients achieved complete remission (CR), 1 patient obtained a partial response (PR) and in 2 cases an hematological improvement (HI) was documented for an overall response rate (ORR) of 19%. Median time to response was 112 days, corresponding to 4 cycles (range 2-14). Marrow response (CR+PR) was significantly associated with overall survival (OS) (p < 0.0001). RASGRP1/APTX was evaluated before treatment initiation on bone marrow (BM), peripheral blood (PB) or both. The median RASGRP/APTX value on BM was 15.3 (15-19.8) in responder patients and 2.2 (0.5-25.9) in non responders, respectively (p = 0.00006). Its median value on PB was 31.6 (19.3- 35.5) in responders and 6.4 (0.5-27.1) in non responders, respectively (p = 0.00001). Interestingly, no marrow responses were recorded in patients with marrow RASGRP1/APTX ratio < 8, while the response rate was 43% (how many were CR?) in patients with RASGRP1/APTX > 8 (p < 0.0001). Finally, RASGRP1/APTX levels significantly correlated with OS (p = 0.001) with a median OS of 490 days and 162 days in patients with RASGRP1/APTX > 8 and < 8 respectively. Conclusions: We conclude that the clinical efficacy of the combination of tipifarnib and bortezomib was evident. We confirmed that the RASGPR1/APTX BM or PB level is an effective predictor of response and survival and our now studying the response of such patients to tipifarnib, alone. Supported by: BolognAIL, AIRC, FIRB 2006. No significant financial relationships to disclose.
TCT-766 Sub-acute Safety and Efficacy Evaluation of a Single versus Double Treatment Cycles of a Monopolar Radiofrequency Catheter-Based Renal Nerve Ablation and its Chronic Evolution in a Large Animal Model
Authors: Armando Tellez, Atsushi Sakaoka, Bradley Hubbard, Irena K. Brants, Krista N. Dillon, Dane A. Brady, Chandan Devireddy, Felix Mahfoud, Serge D. Rousselle
Journal: Journal of the American College of Cardiology (2015)
Osteogenesis: Bone Morphogenetic Protein‐2 Promotes Human Mesenchymal Stem Cell Survival and Resultant Bone Formation When Entrapped in Photocrosslinked Alginate Hydrogels (Adv. Healthcare Mater. 19/2016)
Authors: Steve S. Ho, Nina L. Vollmer, Motasem I. Refaat, Oju Jeon, Eben Alsberg, Mark A. Lee, J. Kent Leach
Journal: Advanced Healthcare Materials (2016)

J. Kent Leach and co-workers investigate the inhibition of apoptosis and promotion of survival and osteogenesis of human mesenchymal stem cells when entrapped in a photocrosslinkable alginate hydrogel on page 2501. The images show the gelation of BMP-2 in alginate with mesenchymal stem cells to be implanted in a segmental defect. In vitro studies demonstrate improved survival of cells when stimulated with BMP-2, translating to improved bone healing in vivo (as shown by microCT).
TCT-578 Predictive Factors of Early, Late and Very Late Atherothrombotic Events in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials
Authors: Gennaro Giustino, Olga Salianski, Melissa Aquino, Samantha Sartori, Giulio G. Stefanini, Martin Leon, Gregg W. Stone, Alaide Chieffo, George Dangas, David Kandzari, Giora Weisz, William C. Wijns, Patrick W. Serruys, Dipti Itchhaporia, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)
A Novel Peptide Containing a Nine Amino Acid Sequence from Nur77 Induces Bcl-2-Dependent Apoptosis in AML.
Authors: Michael Andreeff, Marina Konopleva, Julie C. Watt, Ismael J. Samudio, Arnold C. Satterthwait, Shinichi Kitada, Xiao-kun Zhang, John C. Reed
Journal: Blood (2006)
Whole-Genome Bisulfite Sequencing of Primary AML Cells with the DNMT3A R882H Mutation Identifies Regions of Focal Hypomethylation That Are Associated with Open Chromatin
Authors: David H. Spencer, Bilal Al-Khalil, David Russler-Germain, Tamara Lamprecht, Nicole Havey, Robert S. Fulton, Michelle O'Laughlin, Catrina Fronick, Richard K. Wilson, Timothy J. Ley
Journal: Blood (2014)
Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy
Authors: Ajay K Gopal, Brad S Kahl, Christopher Flowers, Peter Martin, Brian K Link, Stephen Ansell, Wei Ye, Brian Koh, Steve Abella, Paul M. Barr, Gilles A. Salles, Jonathan W. Friedberg
Journal: Blood (2015)